Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | EGFR | P00533 | 2/20 | 0.62 |
| ▸ | PTK2 | Q05397 | 5/20 | 0.59 |
| ▸ | PDGFRA | P16234 | 4/20 | 0.58 |
| ▸ | PDGFRB | P09619 | 2/20 | 0.58 |
| ▸ | ROCK1 | Q13464 | 7/20 | 0.55 |
| ▸ | WEE1 | P30291 | 5/20 | 0.55 |
| ▸ | ALK | Q9UM73 | 5/20 | 0.55 |
| ▸ | JAK2 | O60674 | 4/20 | 0.55 |
| ▸ | AURKA | O14965 | 3/20 | 0.55 |
| ▸ | DAPK3 | O43293 | 3/20 | 0.55 |
| ▸ | PRKD3 | O94806 | 3/20 | 0.55 |
| ▸ | MAP4K4 | O95819 | 3/20 | 0.55 |
| ▸ | PAK4 | O96013 | 3/20 | 0.55 |
| ▸ | LCK | P06239 | 3/20 | 0.55 |
| ▸ | FYN | P06241 | 3/20 | 0.55 |
| ▸ | CSF1R | P07333 | 3/20 | 0.55 |
| ▸ | RET | P07949 | 3/20 | 0.55 |
| ▸ | IGF1R | P08069 | 3/20 | 0.55 |
| ▸ | FGFR1 | P11362 | 3/20 | 0.55 |
| ▸ | PRKACA | P17612 | 3/20 | 0.55 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL3283903 | 0.93 | PDGFRA (0.68) | EGFRPTK2PDGFRAPDGFRBROCK1 | |
| SCHEMBL3281334 | 0.86 | EGFR (0.61) | EGFRPTK2PDGFRAPDGFRBROCK1 | |
| SCHEMBL4198251 | 0.86 | EGFR (0.59) | EGFRPTK2PDGFRAPDGFRBROCK1 | |
| SCHEMBL3280136 | 0.82 | EGFR (0.71) | EGFRPTK2PDGFRAPDGFRBROCK1 | |
| SCHEMBL3279981 | 0.81 | PDGFRB (0.56) | EGFRPTK2PDGFRAPDGFRBROCK1 | |
| SCHEMBL3283451 | 0.81 | PTK2 (0.57) | EGFRPTK2PDGFRAPDGFRBJAK2 | |
| SCHEMBL13406069 | 0.80 | PDGFRA (0.57) | EGFRPTK2PDGFRAPDGFRBROCK1 | |
| SCHEMBL3280599 | 0.80 | PTK2 (0.57) | EGFRPTK2PDGFRAPDGFRBJAK2 | |
| SCHEMBL3279455 | 0.79 | EGFR (0.57) | EGFRPTK2PDGFRAPDGFRBROCK1 | |
| SCHEMBL3286821 | 0.79 | SYK (0.69) | EGFRPTK2PDGFRAPDGFRBALK |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 8 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7705004-B2 | Protein kinase inhibitors | PORTOLA PHARMACEUTICALS, INC. (US) | 2010-04-27 | — | — | US | claimed |
| WO-2009026107-A1 | PROTEIN KINASE INHIBITORS | PORTOLA PHARMACEUTICALS, INC. (US) | 2009-02-26 | — | — | WO | claimed |
| US-20090054425-A1 | PROTEIN KINASE INHIBITORS | PORTOLA PHARMACEUTICALS, INC. (US) | 2009-02-26 | — | — | US | claimed |
| US-7705004-B2 | Protein kinase inhibitors | PORTOLA PHARMACEUTICALS, INC. (US) | 2010-04-27 | — | — | US | disclosed |
| US-7705004-B2 | Protein kinase inhibitors | PORTOLA PHARMACEUTICALS, INC. (US) | 2010-04-27 | — | — | US | disclosed |
| WO-2009026107-A1 | PROTEIN KINASE INHIBITORS | PORTOLA PHARMACEUTICALS, INC. (US) | 2009-02-26 | — | — | WO | disclosed |
| US-20090054425-A1 | PROTEIN KINASE INHIBITORS | PORTOLA PHARMACEUTICALS, INC. (US) | 2009-02-26 | — | — | US | disclosed |
| US-20090054425-A1 | PROTEIN KINASE INHIBITORS | PORTOLA PHARMACEUTICALS, INC. (US) | 2009-02-26 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090054425-A1 | PROTEIN KINASE INHIBITORS | SYK, JAK2, BTK | EGFR 639/4885PTK2 196/4885PDGFRA 454/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.